Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine
Tempus AI, Inc. (NASDAQ: TEM), a tech firm forefront in utilizing AI to enhance precision medicine and patient care, unveiled the nationwide rollout of its OneOme pharmacogenomics (PGx) testing solution. This offering provides in-depth genetic insights to enhance medication safety, dosage, and assessment of toxicity risks. After acquiring OneOme in November 2025, Tempus has seamlessly merged these functions to broaden its extensive precision medicine portfolio.